Skip to main content

Advertisement

Table 3 Adverse events

From: A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer

Adverse events N = 35
Any grade [n (%)] Grade 3/4 [n (%)]
Hematological   
 Neutropenia 34 (97.1) 22 (62.9)
 Leucopenia 31 (88.6) 9 (25.7)
 Anemia 18 (51.4) 0 (0)
 Thrombocytopenia 18 (51.4) 0 (0)
 Febrile neutropenia 2 (5.7) 2 (5.7)
Non-hematological   
 AST 29 (82.9) 1 (2.9)
 ALT 29 (82.9) 0 (0)
 Alopecia 26 (74.3) NA
 Fatigue 22 (62.9) 0 (0)
 Sensory neuropathy 21 (60.0) 1 (2.9)
 Fever 17 (48.6) 0 (0)
 Mucositis 13 (37.1) 1 (2.9)
 Γ-GTP 13 (37.1) 2 (5.7)
 Nausea 11 (31.4) 0 (0)
 Taste disturbance 11 (31.4) 0 (0)
 Anorexia 10 (28.6) 0 (0)
 ALP 9 (25.7) 1 (2.9)
 Skin rash 6 (17.1) 1 (2.9)
 Vomiting 4 (11.4) 0 (0)
 Constipation 4 (11.4) 0 (0)
 Diarrhea 4 (11.4) 0 (0)
 Arthralgia 4 (11.4) 0 (0)
 Edema 4 (11.4) 0 (0)
 Myalgia 3 (6.6) 0 (0)
 Motor neuropathy 2 (5.7) 0 (0)
  1. NA not available, AST aspartate aminotransferase, ALT alanine aminotransferase, GTP gamma-glutamyl transpeptidase, ALP gamma-glutamyl transpeptidase